NDAINTRAVENOUSSOLUTION
Approved
Mar 2020
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
6
Data completeness
3/8 — Basic
Drug data last refreshed 27m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIFERIC AVNU is an intravenous ferric pyrophosphate citrate solution approved by the FDA in March 2020 for iron replacement therapy. It is administered as an IV solution to address iron deficiency in patients requiring dialysis or other clinical settings. The drug delivers bioavailable iron through a novel pyrophosphate citrate complex formulation.
LOE Approaching2.7 years to LOE
Product is approaching loss of exclusivity with limited commercial runway, suggesting focus on operational efficiency and manufacturing optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
Started Apr 2021
12 enrolled
End Stage Renal Disease
Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)
Started Sep 2020
150 enrolled
End Stage Renal Disease
Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.
Started Jun 2020
23 enrolled
End Stage Renal Disease
Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
Started Oct 2017
27 enrolled
End Stage Renal Disease
Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
Started Apr 2016
13 enrolled
End Stage Renal Disease
Worked on TRIFERIC AVNU at Rockwell Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.